EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
Read More
Tag: Erbitux
Merck’s Erbitux backed by NICE for head and neck cancer
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
Read More
NICE expands reach of Erbitux in colorectal cancer
Cost regulators for the NHS treatments in England and Wales are expanding the scope of Merck’s Erbitux so that the therapy will be routinely available to treat a wider range of patients with metastatic colorectal cancer (mCRC).
Read More
Researchers uncover cetuximab resistance pathway in bowel cancer
Researchers from Queen’s University, Belfast, have discovered that blocking a certain molecule could help side-step resistance to cetuximab in bowel cancer patients.
Read More
NICE rejects Merck’s Erbitux
The National Institute for Health and Care Excellence has decided that use of Merck’s head and neck cancer drug Erbitux is not cost-effective for the NHS in England and Wales.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
